The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this Phase I/II clinical trial were presented at the 2011 annual meeting of the American Society of Hematology.
Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell that are part of the body’s immune system. Patients with multiple myeloma have increased numbers of abnormal plasma cells that may produce increased quantities of dysfunctional antibodies detectable in the blood and/or urine.
Carfilzomib is a type of targeted drug known as a proteasome inhibitor. It has produced good results in patients with relapsed or refractory multiple myeloma, and is also being evaluated in patients with earlier-stage disease. Carfilzomib is taken orally (by mouth).
To evaluate carfilzomib among patients with newly diagnosed multiple myeloma, researchers conducted a Phase I/II clinical trial among 53 patients. All patients were treated with a combination of carfilzomib, Revlimid, and low-dose dexamethasone.
- 94 percent of patients had at least a partial response (a partial reduction in detectable cancer) after completing the first cycle of treatment.
- Responses continued to improve with additional treatment cycles. Among patients who had received at least 12 cycles of treatment, all had at least a very good partial response.
- After 9.5 months of follow-up, all of the patients were alive and only one had experienced a worsening (progression) of their cancer.
These results suggest that the combination of carfilzomib, Revlimid, and low-dose dexamethasone is active against newly diagnosed multiple myeloma. Carfilzomib will continue to be evaluated among patients with various stages of multiple myeloma.
Reference: Jakubowiak AJ, Dytfeld D, Jagannath S et al. Final results of a frontline Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Presented at the 53rd ASH Annual Meeting and Exposition.San Diego,CA, December 10-13, 2011. Abstract 631.
Copyright © 2018 CancerConnect. All Rights Reserved.